Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Overview of Tempest Therapeutics Inc
Tempest Therapeutics Inc is a development-stage biotechnology firm dedicated to advancing small molecule therapeutics that modulate anti-tumor immunity pathways. At its core, the company is committed to leveraging innovative immuno-oncology solutions and small molecule therapies to address significant unmet medical needs in cancer treatment. Its approach is centered on designing molecules that not only target tumor cells directly but also enhance tumor-specific immunity, positioning itself as a key player in the evolving landscape of oncology drug development.
Therapeutic Pipeline and Research Focus
The company has assembled a balanced and deep pipeline that includes both first-in-class and best-in-class compounds. These small molecule candidates are engineered to modulate distinct immune response pathways essential for initiating an effective anti-tumor response. The therapeutic programs are developed with a strong foundation in advanced drug discovery technology, originating from Inception Sciences, a drug discovery engine associated with Versant Ventures. This gives the company a robust technological advantage in its quest to refine precision therapies that target multiple aspects of cancer biology.
Clinical and Developmental Stance
Tempest Therapeutics Inc has positioned several of its candidates into clinical-phase evaluations, thereby transitioning from a purely development-stage platform to one that is actively exploring clinical applications. With ongoing trials examining the efficacy and safety of its core candidates, the company is systematically advancing its programs in a rigorous clinical environment. This strategic progression is supported by a team of experienced professionals in small molecule and immuno-oncology drug development who guide the design, development, and anticipated clinical applications of these compounds.
Strategic Research and Industry Positioning
Operating in a highly competitive sector, Tempest Therapeutics Inc differentiates itself through its dual focus on direct anti-tumor activity and immune modulation. The company’s research is deeply embedded in the science of immuno-oncology, an area that demands a sophisticated understanding of cancer immunology and intricate pathway modulation. The therapeutic strategy leverages a detailed grasp of the tumor microenvironment and the dynamic interplay of immune responses, which is critical for developing compounds with meaningful clinical utility.
Key Attributes and Technological Foundations
- Innovative Pipeline: A portfolio of candidate molecules that are designed to work through novel mechanisms, offering potential breakthroughs in cancer treatment.
- Scientific Rigor: Research and development processes underscored by advanced methodologies, ensuring that therapeutic strategies are grounded in robust scientific principles.
- Experienced Leadership: A multidisciplinary team with extensive backgrounds in drug discovery and clinical development, providing deep expertise in tackling the complexities of immuno-oncology.
- Collaborative Foundations: Early discovery efforts linked to established drug discovery engines, emphasizing a collaborative approach in identifying and optimizing promising therapeutic candidates.
Market Impact and Significance
Within the competitive landscape of biotechnology and oncology, Tempest Therapeutics Inc stands out through its commitment to addressing critical gaps in cancer therapeutics. Its strategic focus combines both innovation and scientific depth, allowing the company to explore multiple therapeutic avenues within the broader framework of immunotherapy. The integration of first-in-class and best-in-class designations in its pipeline reflects an effort to not only innovate but also refine treatment strategies that can be pivotal in a clinical setting. This solid strategic foundation is supported by a syndicate of venture capital firms from the US and China, underscoring a level of confidence in the company’s research and development approach from prominent investors.
Understanding the Business Model
Tempest Therapeutics Inc operates under a business model typical of clinical-stage biotechnology companies. Its focus on targeted small molecule therapeutics allows it to address niche segments within the oncology market, where precision medicine and immune modulation are becoming increasingly critical. The company generates value primarily through its progressive pipeline development rather than immediate product sales, with its future phases hinging on the successful demonstration of clinical efficacy and safety in its therapeutic candidates. This model necessitates a balanced approach to risk management and innovation, anchored by rigorous pre-clinical and clinical evaluations.
Comprehensive Insights for Investors and Researchers
The detailed exploration of Tempest Therapeutics Inc reveals a company that is meticulously engineered to push the boundaries of current cancer treatment paradigms. Every element of its design, from its selection of therapeutic targets to its strategic partnership with drug discovery experts, speaks to a comprehensive and nuanced approach in biotech innovation. For stakeholders and researchers seeking a deep dive into emerging immuno-oncology therapies, the operational framework and development pipeline of Tempest Therapeutics Inc provide both a rich context and a wealth of actionable insights.
This comprehensive narrative is designed to offer clarity and depth for those interested in understanding the operational, scientific, and strategic nuances that define Tempest Therapeutics Inc. The description encapsulates the essence of the company’s mission, research endeavors, and market positioning without venturing into forecasts or speculative financial outcomes, thereby serving as an evergreen resource for investment research and academic interest.
Tempest Therapeutics (NASDAQ: TPST) reported significant progress in 2024, highlighted by key developments for their cancer therapeutics. Their lead drug Amezalpat received both Orphan Drug and Fast Track designations from the FDA for Hepatocellular Carcinoma (HCC) treatment. The company secured an agreement with Roche to advance Amezalpat into a Phase 3 trial.
Clinical results showed Amezalpat delivered a six-month improvement in median overall survival when combined with standard treatments for HCC. For TPST-1495, the company received FDA clearance for a Phase 2 trial in Familial Adenomatous Polyposis.
Financial results showed cash position of $30.3 million at year-end, down from $39.2 million in 2023. Net loss increased to $41.8 million ($1.50 per share) compared to $29.5 million ($1.91 per share) in 2023. R&D expenses rose to $28.5 million from $17.5 million, while G&A expenses increased to $13.6 million from $11.7 million.
Tempest Therapeutics (NASDAQ: TPST) has announced that data supporting the immune component of amezalpat's mechanism of action will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The presentation, which will be in poster format, is scheduled to take place during the conference running from April 25-30, 2025 in Chicago, IL. The abstract highlights clinical data that reinforces amezalpat's potential as a novel cancer treatment.
Tempest Therapeutics (TPST) has received FDA clearance to proceed with a Phase 2 clinical trial for TPST-1495, their novel dual receptor inhibitor of prostaglandin signaling, to treat Familial Adenomatous Polyposis (FAP). This marks the company's second clinical program entering Phase 2, with data expected in 2026.
The study will be conducted by the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute's Division of Cancer Prevention. The trial aims to develop new treatment options for FAP, a high-risk condition that significantly increases the risk of multiple GI cancers. The Phase 2 study is scheduled to begin in 2025.
Tempest Therapeutics (NASDAQ: TPST) has received Fast Track Designation (FTD) from the FDA for amezalpat, their oral PPAR⍺ antagonist drug for treating hepatocellular carcinoma (HCC). This follows the Orphan Drug Designation (ODD) granted in January after positive Phase 1b/2 clinical trial results.
The global randomized study evaluated amezalpat combined with standard-of-care atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone in first-line treatment of unresectable or metastatic HCC. Key results showed a six-month improvement in median overall survival with a hazard ratio of 0.65 for patients receiving the combination therapy. The survival benefit was maintained in key sub-populations, including PD-L1 negative disease patients, supporting amezalpat's proposed mechanism targeting both tumor cells and the patient's immune system.
Tempest Therapeutics (TPST), a clinical-stage biotech company focused on developing targeted cancer therapeutics, has announced a new employee compensation grant. The company's Compensation Committee approved nonqualified stock options for one employee to purchase 45,000 shares of common stock under its 2023 Inducement Plan. The options will vest over four years, with 25% vesting after the first year and the remaining portion vesting at 1/48th monthly thereafter, contingent on continued employment.
Tempest Therapeutics announced that the FDA has granted Orphan Drug Designation to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist, for the treatment of patients with hepatocellular carcinoma (HCC).
According to Sam Whiting, M.D., Ph.D., this designation highlights the critical need for new treatments for this challenging disease. Tempest plans to proceed with a pivotal phase 3 study for amezalpat in first-line HCC patients.
The designation follows positive data from a global randomized Phase 1b/2 clinical study evaluating amezalpat plus standard-of-care atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone in treating unresectable or metastatic HCC. Key results include:
- A six-month improvement in median overall survival (OS) with a hazard ratio (HR) of 0.65 for the amezalpat combination therapy.
- An objective response rate (ORR) of 30% compared to 13% for the control arm.
- Preserved survival benefit in key sub-populations, including PD-L1 negative disease and b-catenin mutated disease.
These outcomes are consistent with amezalpat’s mechanism of action, targeting both tumor cells and the patient’s immune system.
Tempest Therapeutics (Nasdaq: TPST) announced that its Compensation Committee has granted stock options to one employee under the company's 2023 Inducement Plan. The grant consists of nonqualified stock options to purchase 9,450 shares of common stock. The options will vest over a four-year period, with 25% vesting on the first employment anniversary and the remaining 1/48th vesting monthly thereafter, contingent on continued employment.
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotech company focused on developing first-in-class targeted and immune-mediated cancer therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management will engage in a fireside chat on Tuesday, December 3, 2024 at 9:00 a.m. ET. Interested parties can access both live and archived recordings of the discussion through the investor section of Tempest's website at ir.tempesttx.com.
Tempest Therapeutics (NASDAQ: TPST) reported Q3 2024 financial results and key developments. The company received FDA's 'Study May Proceed' letter for a pivotal Phase 3 trial of amezalpat combination therapy for first-line HCC treatment. Tempest announced an agreement with Roche to support amezalpat's advancement and received NCI funding approval for TPST-1495 Phase 2 trial in FAP.
Financial highlights include: Q3 cash position of $22.1M, net loss of $10.6M ($0.41 per share), and R&D expenses of $7.6M. The company raised additional $19.9M through ATM offering post-quarter. Year-to-date operating cash burn was $22.9M with a net loss of $28.0M ($1.19 per share).
Tempest Therapeutics (Nasdaq: TPST) announced receiving a 'Study May Proceed' letter from the FDA for a pivotal Phase 3 trial of amezalpat (TPST-1120) combined with atezolizumab and bevacizumab. This trial will compare this combination against the current standard of care alone in treating first-line unresectable or metastatic hepatocellular carcinoma (HCC). Chief Medical Officer Sam Whiting highlighted the potential of amezalpat to improve patient survival, citing positive Phase 2 data. The company aims to advance this program to benefit patients with this life-threatening disease.
FAQ
What is the current stock price of Tempest Therapeutics (TPST)?
What is the market cap of Tempest Therapeutics (TPST)?
What is the primary focus of Tempest Therapeutics Inc?
How does the company differentiate its therapeutic approach?
What stage of development is the company currently in?
What role does immuno-oncology play in Tempest Therapeutics Inc's pipeline?
How does the company support its drug development efforts?
What are the key aspects of its business model?
How is Tempest Therapeutics Inc positioned within the oncology market?
Who typically supports the company in its development efforts?
